1 – 5 of 5
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
(
- Contribution to journal › Article
- 2015
-
Mark
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation.
(
- Contribution to journal › Article
- 2011
-
Mark
Challenges to the Development of New Agents for Molecularly Defined Patient Subsets: Lessons From BRCA1/2-Associated Breast Cancer
(
- Contribution to journal › Debate/Note/Editorial
- 2010
-
Mark
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
(
- Contribution to journal › Article
-
Mark
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
(
- Contribution to journal › Article